Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

ClinicalTrials.gov ID: NCT00363727

Public ClinicalTrials.gov record NCT00363727. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects.

Study identification

NCT ID
NCT00363727
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
209 participants

Conditions and interventions

Interventions

  • ropinirole controlled-release (REQUIP CR) for RLS Drug

Drug

Eligibility (public fields only)

Age range
30 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2003
Primary completion
Dec 31, 2005
Completion
Dec 31, 2005
Last update posted
Jan 17, 2017

2003 – 2006

United States locations

U.S. sites
69
U.S. states
27
U.S. cities
64
Facility City State ZIP Site status
GSK Investigational Site Anniston Alabama 36207
GSK Investigational Site Birmingham Alabama 35216
GSK Investigational Site Birmingham Alabama 35294
GSK Investigational Site Phoenix Arizona 85006
GSK Investigational Site Sun City Arizona 85351
GSK Investigational Site Tucson Arizona 85712
GSK Investigational Site La Jolla California 92037
GSK Investigational Site Los Angeles California 90033
GSK Investigational Site Newport Beach California 92660
GSK Investigational Site Oxnard California 93030
GSK Investigational Site San Jose California 95126
GSK Investigational Site Walnut Creek California 94596
GSK Investigational Site Boulder Colorado 80304
GSK Investigational Site Danbury Connecticut 06810
GSK Investigational Site Newark Delaware 19713
GSK Investigational Site Boca Raton Florida 33486
GSK Investigational Site Fort Lauderdale Florida 33145
GSK Investigational Site Gainesville Florida 32611
GSK Investigational Site Miami Florida 33143
GSK Investigational Site Palm Beach Gardens Florida 33410
GSK Investigational Site Pembroke Pines Florida 33026
GSK Investigational Site Port Charlotte Florida 33952
GSK Investigational Site Tampa Florida 33606
GSK Investigational Site Tampa Florida 33612
GSK Investigational Site Augusta Georgia 30912
GSK Investigational Site Austell Georgia 30106
GSK Investigational Site Columbus Georgia 31901
GSK Investigational Site Decatur Georgia 30033
GSK Investigational Site Boise Idaho 83702
GSK Investigational Site Chicago Illinois 60611
GSK Investigational Site Chicago Illinois 60637
GSK Investigational Site Hoffman Estates Illinois 60194
GSK Investigational Site Northbrook Illinois 60062
GSK Investigational Site Des Moines Iowa 50309-1426
GSK Investigational Site Kansas City Kansas 66160
GSK Investigational Site Elkridge Maryland 21075
GSK Investigational Site South Weymouth Massachusetts 2190
GSK Investigational Site West Yarmouth Massachusetts 02673
GSK Investigational Site Bingham Farms Michigan 48025
GSK Investigational Site Grand Rapids Michigan 49503
GSK Investigational Site Traverse City Michigan 49684
GSK Investigational Site Las Vegas Nevada 89109
GSK Investigational Site Edison New Jersey 08818
GSK Investigational Site Albany New York 12205
GSK Investigational Site Amherst New York 14226
GSK Investigational Site Rochester New York 14603
GSK Investigational Site Asheville North Carolina 28801
GSK Investigational Site Chapel Hill North Carolina 27516
GSK Investigational Site Raleigh North Carolina 27607
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Cincinnati Ohio 45267-0525
GSK Investigational Site Eugene Oregon 97401
GSK Investigational Site Medford Oregon 97504-8456
GSK Investigational Site Philadelphia Pennsylvania 19104
GSK Investigational Site Austin Texas 78756
GSK Investigational Site Dallas Texas 75231
GSK Investigational Site Dallas Texas 75235
GSK Investigational Site Houston Texas 77030
GSK Investigational Site Houston Texas 77081
GSK Investigational Site Lubbock Texas 79410
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Alexandria Virginia 22311
GSK Investigational Site Richmond Virginia 23226
GSK Investigational Site Roanoke Virginia 24014
GSK Investigational Site Kirkland Washington 98034
GSK Investigational Site Seattle Washington 98101
GSK Investigational Site Tacoma Washington 98405
GSK Investigational Site Charleston West Virginia 25301
GSK Investigational Site Madison Wisconsin 53715

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00363727, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 17, 2017 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00363727 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →